Frontage introduces a new ultrasensitive assay for the quantitative determination of pTau217 in human plasma, serum, and cerebrospinal fluid (CSF), one of the most promising blood-based biomarkers of Alzheimer’s disease.
Register to gain access to gated resources.
Thank you for registering!
You now have the option of downloading the resource or viewing the web version below.
Frontage offers an impressive list of biomarker assays. Download our ever-growing list of biomarker assays to find what you need. Don't see what you're looking for? Contact us for your custom assay requests.
In this eBook, we navigate the landscape of biomarker discovery through genomic profiling, exploring technologies, methods, and applications. We hope this collection of articles creates an appreciation for the wide scope of using sequencing assays for biomarker discovery, drug development, and beyond.
It has been said that the diagnosis of Alzheimer's disease enters the era of biomarkers. These two biomarkers, amyloids, and taus, defines Alzheimer's disease. In this presentation, Dr. Kai Wang, Senior Director of Biomarker Services at Frontage Laboratories, Inc, focuses on highly sensitive protein biomarker assays developed and validated at a testing laboratory and their application for the diagnosis of Alzheimer's disease.